Altimmune, Inc. (NASDAQ:ALT – Get Free Report) CFO Gregory L. Weaver acquired 10,000 shares of the firm’s stock in a transaction dated Thursday, March 13th. The shares were purchased at an average price of $5.20 per share, with a total value of $52,000.00. Following the acquisition, the chief financial officer now owns 10,000 shares of the company’s stock, valued at approximately $52,000. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Altimmune Price Performance
Shares of NASDAQ:ALT opened at $5.92 on Friday. The company has a market capitalization of $455.92 million, a PE ratio of -3.82 and a beta of 0.87. The business has a fifty day moving average price of $6.48 and a two-hundred day moving average price of $7.11. Altimmune, Inc. has a 1 year low of $5.14 and a 1 year high of $11.16.
Altimmune (NASDAQ:ALT – Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. Sell-side analysts anticipate that Altimmune, Inc. will post -1.35 earnings per share for the current year.
Analysts Set New Price Targets
Get Our Latest Stock Report on Altimmune
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in ALT. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Altimmune by 119.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 40,705 shares of the company’s stock valued at $250,000 after buying an additional 22,188 shares during the last quarter. Intech Investment Management LLC purchased a new stake in Altimmune during the 3rd quarter worth about $207,000. Charles Schwab Investment Management Inc. lifted its holdings in Altimmune by 2.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock worth $1,299,000 after purchasing an additional 4,772 shares in the last quarter. Larson Financial Group LLC purchased a new stake in Altimmune during the 3rd quarter worth about $31,000. Finally, Summit Financial Wealth Advisors LLC lifted its holdings in Altimmune by 65.1% during the 3rd quarter. Summit Financial Wealth Advisors LLC now owns 45,918 shares of the company’s stock worth $282,000 after purchasing an additional 18,113 shares in the last quarter. Hedge funds and other institutional investors own 78.05% of the company’s stock.
Altimmune Company Profile
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
See Also
- Five stocks we like better than Altimmune
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Why Costco Stock Is Poised to Hit $1,000 Again Soon
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- MarketBeat Week in Review – 03/10 – 03/14
- Profitably Trade Stocks at 52-Week Highs
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.